Head-to-head · WeighScore
LillyDirect Foundayo vs RxSpan MD
By GLP-1 ScorecardUpdated
Score comparison
RxSpan MD has the higher recorded score — 84.3/100 to 67.2/100.
RxSpan MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. RxSpan MD's live catalog lists brand-name GLP-1 drugs, while its homepage also advertises compounded plans; confirm the actual product and total price before enrolling.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | LillyDirect Foundayo | RxSpan MD |
|---|---|---|
| WeighScore | 67.2/100 | 84.3/100 |
| Grade | C | B |
| Site position | #185 | #5 |
| Semaglutide | Not disclosed | Current compounded quote unconfirmed |
| Tirzepatide | Not disclosed | Current compounded quote unconfirmed |
| Coverage | All 50 states | Confirm treatment availability during intake |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Not confirmed |
Site position #185 · C
Strengths
- Manufacturer savings may be available to eligible patients; check the current terms and insurance requirements
- Direct from manufacturer — no compounding, no third-party reseller
- Daily oral tablet; the prescribing information permits taking it with or without food
- Available in all 50 states
What to consider
- Foundayo's placebo-controlled trial results do not establish a direct comparison with Wegovy or Zepbound
- Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
- $25 savings card requires commercial insurance — Medicare and Medicaid not eligible
- Medication interactions and individual suitability need a prescriber's review
Site position #5 · B
Strengths
- Current public catalog lists Ozempic, Wegovy, Mounjaro and Zepbound
- Public terms describe independent healthcare providers
- Homepage describes messaging and care-team appointments
What to consider
- Homepage advertises compounded plans that the current catalog did not substantiate
- Current oral GLP-1 availability is unconfirmed
- Prior compounded prices are not a current quote; selected dose, supply, pharmacy and fee inclusions need confirmation
- Public terms do not establish unused prepaid-treatment refund amounts
Featured provider
RxSpan MD
RxSpan MD scores 84.3/100 (B). RxSpan MD's live catalog lists brand-name GLP-1 drugs, while its homepage also advertises compounded plans; confirm the actual product and total price before enrolling.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.